Loading...
Market
Primary Indication for HS-10535 at First Approval by 2026?
2
Resolution / Starting Odds
Weight Reduction • 25%
Cardiovascular Benefits • 25%
Diabetes Management • 25%
Other • 25%
Approval documentation and press releases
Story
Merck Acquires Rights to HS-10535, a Chinese GLP-1 Receptor Agonist, in $2 Billion Deal with Hansoh Pharma
Dec 18, 2024, 11:58 AM
Merck & Co. Inc. has entered into an exclusive global license agreement with Hansoh Pharma, a Chinese biopharmaceutical company, to develop, manufacture, and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with the potential for up to $1.9 billion in milestone payments related to the development, regulatory approval, and commercialization of the drug, along with royalties on sales. Merck aims to leverage this agreement to enhance its pipeline and explore the potential of HS-10535 to provide cardiometabolic benefits beyond weight reduction. Hansoh Pharma may co-promote or solely commercialize the drug in China under certain conditions.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
B-cell malignancies • 25%
Autoimmune diseases • 25%
Both • 25%
Neither • 25%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
MHRA (UK) • 25%
Other • 25%
